Implications: The present study provides evidence that RAF inhibitor-resistant melanoma cells benefit from continued therapy.
INTRODUCTION
Dysregulated extracellular regulated kinase 1/2 (ERK1/2) signaling has been linked to a number of malignancies including melanoma. Approximately 50% of melanoma patients present with a mutation in the serine-threonine kinase BRAF; most mutations alter codon 600 from a valine to glutamic acid (V600E) (1) . The V600E mutation leads to a constitutively active kinase form of BRAF, which aberrantly signals to its downstream target, mitogen-activated protein kinase kinase (MEK) (2) . Activated MEK phosphorylates ERK1/2, which in turn phosphorylates transcription factors that control a number of proliferative and anti-apoptotic targets.
The landscape of treatment options for patients suffering from metastatic BRAF V600E melanoma drastically changed with the introduction of targeted RAF inhibitors (3) . Vemurafenib/PLX4032 and dabrafenib, which are both FDA-approved drugs, act as ATP-competitive inhibitors of BRAF V600E . RAF inhibitors achieve clinical response rates of approximately 50% and the median progression-free survival is 5-7 months (4, 5) . However, most of the patients who initially respond will develop resistance to the treatment and ultimately succumb to the disease (5) . RAF inhibitor resistance is currently a major challenge for the melanoma field.
Multiple mechanisms of RAF inhibitor resistance have been demonstrated, most of which funnel through re-activation of ERK1/2 (reviewed in (6) ). Previous work has identified multiple mechanisms of resistance including upregulation of the receptor tyrosine kinases (RTKs) PDGFRβ and IGF-1R, BRAF amplification, COT expression, mutation of RAS isoforms, and mutations in MEK1 and MEK2 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . However, the most frequent mechanism identified to date is the expression of BRAF variants lacking the RAS binding domain (7, 9) . Despite RAS-binding defects, these variants retain RAF kinase activity in the presence of vemurafenib due to their enhanced homodimerization properties (7, 9) .
The treatment options for patients progressing on vemurafenib or dabrafenib are limited. Disease progression is often too rapid for immune treatments such ipilimumab to elicit effects and, hence, standard chemotherapies are usually administred (17) (18) (19) . In order to provide a preclinical basis for possible second-line treatment strategies for patients progressing on RAF inhibitor, the effect of inhibitor withdrawl or a "drug holiday" has been investigated. Cessation of targeted inhibitor treatment has been suggested to exploit the adaptive mechanisms that cells may utilize to preserve ERK1/2 signaling (20) . In one study, a drug holiday was shown to be efficacious for a melanoma cell line in which RAF inhibitor resistance was mediated by BRAF copy number amplification (21) . In contrast, an independent study showed that BRAF V600E melanoma patients progressing on vemurafenib or dabrafenib experienced rapid disease progression after cessation of the treatment regimen, suggesting that presence of RAF inhibitor was slowing growth of the resistant cells (8). These data seemingly oppose each other and suggest that many factors may be involved in determining the response of resistant cells to RAF inhibitors. To further examine this, we tested the effects of a drug holiday on the growth and signaling of in vivo-derived RAF inhibitor resistant cell lines that express BRAF V600E splice variants.
MATERIALS AND METHODS
Cell culture: 1205Lu ERK1/2 reporter cells were generated by transducing cells with UAS/EGFP firefly luciferase and UbC/GAL4-ELK1 constructs. Full procedures are described in (7) . PRT #3 and PRT #4 cells express the BRAF V600E splice variants, ΔEx3-10 and ΔEx 2-8, respectively (7) . Cells were cultured in 37˚C humidified chamber supplemented with 5% CO 2 in MCDB 153 media containing 20% Leibovitz-L15 media, 2% fetal bovine serum, 0.2% sodium bicarbonate, and 5μg/mL insulin. PRT lines were maintained in 1μM PLX4720.
Inhibitors: PLX4720 and PLX4720 rodent chow was provided by Dr. Gideon Bollag (Plexxikon Inc., Berkeley, CA). Trametinib was purchased from Selleck (Houston, TX).
Proliferation assay: Cells (1.4 x 10 4 ) were seeded in 6 well dishes. Medium and indicated drugs were replenished every 2 days. After nine days, plates were washed in PBS and fixed in buffered formalin with 0.2% crystal violet. Plates were then scanned and percent area coverage was quantified using ImageJ software. Displayed images are representative and the associated graphs are normalized composites of at least 3 independent experiments. Error bars are +/-standard error of the mean (SEM).
Significance was determined with the use of two-tailed student's t-test assuming unequal variance. p values less than 0.05 were considered significant. In our previous work, we have shown that the expression of BRAF variants in PRT #3 and PRT #4 cells is necessary for RAF inhibitor resistance and also that no alterations in NRAS, MEK1 and MEK2 were detected (7). Additionally, Western blot analysis revealed no obvious up-regulation of Akt signaling that can provide an ERK1/2 pathway-independent mode of resistance (Supplemental Fig. 1 ). We subjected these two cell lines, PRT #3 (expresses BRAF selection to PLX4720, we wanted to examine if the benefit of PLX4270 treatment observed in vitro would be replicated in vivo. In previous studies, we have shown that the growth of parental cell xenografts in athymic mice is effectively blocked by PLX4720 treatment but continued treatment gave rise to the resistant cell lines, PRT #3 and PRT #4 which are able to growth in the presence of PLX4720 (7). Here, we determined the effect of PLX4720 withdrawal on PRT #3 and PRT #4 xenografts by dividing mice into two cohorts: one receiving vehicle chow; the other receiving PLX4720-laced chow. When tumor growth was measured over 21 days, PLX4720 treatment produced a significant increase in the mean tumor size in both PRT #3 and PRT #4 xenografts compared to the vehicle-treated (drug-removed) xenografts ( Fig. 2A, 2B) . To determine the possible cause of this enhanced growth, tumors were harvested from mice in each of the cohorts and cell cultures generated. Tumor cells from the indicated mouse were cultured short term (P2) in tissue culture plates maintaining the presence or absence of 1μM PLX4720 to mimic the in vivo setting. Western blotting of lysates revealed an increased state of ERK1/2 phosphorylation in the vehicle-treated PRT cells compared to PLX4720-treated PRT cells (Fig. 2C, 2D ). These in vivo data support the notion that RAF inhibitor may increase the proliferation of mutant BRAF splice variant-expressing cells by maintaining a lower phospho-ERK steady state.
Phospho-ERK1/2 is elevated in PRT cell lines after RAF inhibitor removal. We further explored the phospho-ERK1/2 status by utilizing PRT #3 and PRT #4 cells in in vitro studies. When cultured in 1μM PLX4720, PRT #3 and PRT #4 displayed levels of phospho-ERK1/2 that were comparable to untreated levels in parental cells (Fig. 3A) . 
However, overnight removal of PLX4720 strongly increased the ERK1/2 activation in both PRT #3 and PRT #4 cells (Fig. 3A) . Drug removal was also associated with a morphological change to an elongated and spindle-like appearance, consistent with morphology changes observed during elevated ERK1/2 signaling (23) (Supplemental Fig.   3 ). In time course experiments, PLX4720 removal from PRT #3 and PRT #4 cell cultures demonstrated enhanced phosphorylation of MEK and ERK1/2 by 30 minutes, and the elevated phosphorylation state was maintained throughout a 16 hour time course (Fig. 3B) . Consistent with aberrantly high ERK1/2 activity inhibiting cell cycle progression (24) (25) (26) , enhanced levels of cyclin dependent kinase (CDK) inhibitors p21 Cip1 and p27
Kip1
were observed following PLX4720 withdrawal (Fig. 3C ). In addition, the ERK1/2 target Sprouty2 (27) 
parental 1205Lu cells were subjected to proliferation assays in the presence of an escalating dose of GSK'212 (Fig. 4A, 4B) . In both PRT cell lines, a low dose (1nM) of GSK'212 was able to increase cell growth (PRT #3 p <0.0132, PRT #4 p < 0.029), similar to the effects we observed with a 1μM dosage of PLX4720 (Fig. 1) . This was further highlighted by EdU incorporation of PRT #3 and PRT #4 where S-phase entry was significantly higher in cells treated with 1nM GSK'212 (Fig. 4C) . Additionally, western blot analysis demonstrated that 1nM GSK'212 reduced the ERK1/2 phosphorylation to similar levels as 1μM PLX4720 treatment, suggesting that both of these drugs reduces the unfavorable ERK hyperactivation in non-treated BRAF variantexpressing resistant cells (Fig. 4D ).
We further explored the effect of GSK'212 by combining it with PLX4720. We compared parental 1205Lu cells, PRT #3, and PRT #4 in 2D growth assays when these cells were challenged with GSK'212 monotherapy, or the combination of GSK'212 with 1μM PLX4720. As expected the combination of GSK'212 and PLX4720 was more effective than GSK'212 monotherapy at inhibiting the growth of parental 1205Lu cells (Supplemental Fig. 4A) . Moreover, the combination of drugs slowed the growth of PRT #3 and #4 cells. At 1, 5, and 50nM GSK'212/PLX4720 combination a significant reduction in growth of PRT #3 was observed compared to GSK'212 monotherapy (p = 0.021, p = 0.041, and p = 0.018, respectively). Similarly, a significant reduction of growth under combination treatment was observed in PRT #4 at 10 and 20nM GSK'212 concentrations (p = 0.006 and p = 0.035, respectively). In addition, western blots were performed after overnight treatments at similar drug concentrations to assess ERK1/2 activation status (Supplemental Fig 4B) . As anticipated, the phosphorylation of ERK1/2 was ablated at lower concentrations of GSK'212 when combined with treatment of PLX4720.
Taken together, these data suggest that GSK'212 is able to provide the same benefit afforded to proliferation and S-phase entry of the PRT cell lines as PLX4720 treatment. Similar to PLX4720, GSK'212 also was able to substantially reduce cell growth and ERK1/2 phosphorylation at higher concentrations, (~5nM and higher) suggesting that both drugs are able to suppress phospho ERK1/2 levels below the homeostatic threshold. Additionally, the combination of PLX4720 and GSK'212, elicited a more potent reduction in proliferation and ERK1/2 phosphorylation when compared to GSK'212 alone. from RAF inhibitor treatment (29) . Subsequent re-challenge with RAF inhibitor led to a significant reduction in tumor burden as well as an increase in overall well-being as measured by Kamofsky score in both patients (29) . This report suggests that RAF inhibitor resistant tumors can become re-sensitized after a drug free interval. It also further highlights the apparent heterogeneity of tumor response observed after RAF inhibitor cessation.
The in vitro and xenograft model studies in this work add to this notion of heterogeneity in cellular response from drug removal in acquired RAF inhibitor resistant cells. Our experimental system utilized two in vivo-derived, RAF inhibitor-resistant cell lines, both of which harbor a BRAF splice variant lacking the RAS binding domain as the mediator of RAF inhibitor resistance (7). We found that both of these cell lines experience a growth advantage in the presence of RAF inhibitor. Our data also suggest that there is a "window" of ERK1/2 activity that seems to be beneficial to the BRAF variant expressing resistant tumor cells. When RAF inhibitor concentration is too low (or absent), ERK1/2 phosphorylation is hyperelevated and may contribute to the stabilization of CDK inhibitors p21 Cip1 and p27 Kip1 . Conversely, when the RAF inhibitor concentration is high enough, RAF activity is indeed blocked leading to a loss of ERK1/2 signaling and ultimately cell death. It is also possible that this window may also be achieved by low doses of the BRAF and MEK inhibitor combination.
Presently, it is unknown why the patients in the Carlino study had a different response to RAF inhibitor cessation compared to the results reported here. It is possible that upon RAF inhibitor withdrawal, the magnitude of ERK1/2 reactivation in the patientderived resistant tumors is not as high as the level we observed in our in vivo-derived 
